London, UK – 31 October 2023 – Leucid Bio (“Leucid” or the “Company”), a privately-held biotechnology company pursuing the development of innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies using the Company’s proprietary Lateral CAR platform, today announced that management will be participating in the following upcoming investor conferences during the month of November:
BIO-Europe at Messe München, Munich, Germany. Leucid Bio management will be hosting 1-on-1 meetings from November 6 – 8.
LSX Investival Showcase at Old Billingsgate, London, UK. Filippo Petti, Chief Executive Officer, is scheduled to present on Monday, November 13, at 12:45 pm GMT.
Jefferies London Healthcare Conference at The Waldorf Hilton in London, UK. Leucid Bio management will be hosting 1-on-1 meetings from November 14 – 16.